Topal, A.; Akdag, G.; Yildirim, S.; Kinikoglu, O.; Isik, D.; Yildirim, G.; Tunbekici, S.; Kus, F.; Acarbay, A.; Guliyev, M.;
et al. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. Medicina 2025, 61, 490.
https://doi.org/10.3390/medicina61030490
AMA Style
Topal A, Akdag G, Yildirim S, Kinikoglu O, Isik D, Yildirim G, Tunbekici S, Kus F, Acarbay A, Guliyev M,
et al. Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. Medicina. 2025; 61(3):490.
https://doi.org/10.3390/medicina61030490
Chicago/Turabian Style
Topal, Alper, Goncagul Akdag, Sedat Yildirim, Oguzcan Kinikoglu, Deniz Isik, Gizem Yildirim, Salih Tunbekici, Fatih Kus, Aydın Acarbay, Murad Guliyev,
and et al. 2025. "Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study" Medicina 61, no. 3: 490.
https://doi.org/10.3390/medicina61030490
APA Style
Topal, A., Akdag, G., Yildirim, S., Kinikoglu, O., Isik, D., Yildirim, G., Tunbekici, S., Kus, F., Acarbay, A., Guliyev, M., Majidova, N., Kutlu, Y., Erman, M., Odabas, H., Turan, N., & Karadurmus, N.
(2025). Efficacy and Clinical Outcomes of Crizotinib in Patients with ROS1-Rearranged NSCLC: A Multicenter Study. Medicina, 61(3), 490.
https://doi.org/10.3390/medicina61030490
